chloroquine has been researched along with didanosine in 15 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (13.33) | 18.2507 |
2000's | 3 (20.00) | 29.6817 |
2010's | 10 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Azas, N; Casano, G; Dumètre, A; Hutter, S; Pannecouque, C; Robin, M | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Costa, J; Dumontet, V; Leyssen, P; Litaudon, M; Neyts, J; Nothias-Scaglia, LF; Pannecouque, C; Paolini, J; Retailleau, P; Roussi, F | 1 |
Girard-Valenciennes, E; Grondin, I; Leyssen, P; Litaudon, M; Neyts, J; Olivon, F; Palenzuela, H; Pannecouque, C; Roussi, F | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
Boelaert, JR; Sperber, K | 1 |
Boelaert, JR; Piette, J; Sperber, K | 1 |
Engchanil, C; Kosalaraksa, P; Lulitanond, V; Lumbiganon, P; Pongjunyakul, P; Suwan-apichon, O; Thuennadee, R; Tungsawad, S | 1 |
1 review(s) available for chloroquine and didanosine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for chloroquine and didanosine
Article | Year |
---|---|
Therapeutic potential of chloroquine added to zidovudine plus didanosine for HIV-1 infected children.
Topics: Anti-HIV Agents; Antimalarials; Child; Child, Preschool; Chloroquine; Didanosine; Female; HIV Infections; HIV-1; Humans; Male; Zidovudine | 2006 |
13 other study(ies) available for chloroquine and didanosine
Article | Year |
---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Anti-HIV and antiplasmodial activity of original flavonoid derivatives.
Topics: Anti-HIV Agents; Antimalarials; Cell Line; Cell Survival; Flavonoids; HIV; HIV Infections; Humans; Malaria, Falciparum; Plasmodium falciparum | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Jatrophane diterpenes as inhibitors of chikungunya virus replication: structure-activity relationship and discovery of a potent lead.
Topics: Alphavirus Infections; Antiviral Agents; Chikungunya Fever; Chikungunya virus; Diterpenes; Euphorbia; France; HIV-1; HIV-2; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Semliki forest virus; Sindbis Virus; Structure-Activity Relationship; Virus Replication | 2014 |
Antiviral Activity of Flexibilane and Tigliane Diterpenoids from Stillingia lineata.
Topics: Antiviral Agents; Chikungunya virus; Diterpenes; Euphorbiaceae; France; HCT116 Cells; HIV-1; HIV-2; Humans; Macrocyclic Compounds; MCF-7 Cells; Molecular Structure; Semliki forest virus; Sindbis Virus; Virus Replication | 2015 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Antiretroviral treatment.
Topics: Anti-HIV Agents; Chloroquine; Developing Countries; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Hydroxyurea | 1998 |
Chloroquine exerts an additive in vitro anti-HIV type 1 effect when associated with didanosine and hydroxyurea.
Topics: Anti-HIV Agents; Apoptosis; Cells, Cultured; Chloroquine; Didanosine; Drug Synergism; HIV-1; Humans; Hydroxyurea; Monocytes; Reverse Transcriptase Inhibitors; T-Lymphocytes; U937 Cells; Virus Replication | 1999 |